Originally published by our sister publication Clinical Oncology News
The FDA approved mosunetuzumab-axgb (Lunsumio, Genentech) for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Mosunetuzumab-axgb, a CD20xCD3 T-cell–engaging bispecific antibody, represents a new class of fixed-duration cancer immunotherapy, which is off-the-shelf and readily available so that patients do not have to delay treatment.